SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss ...
"This quarter we have made progress against our key objectives and have seen meaningful progress on our Gen 2 R1 cost structure due to the new technologies incorporated into the vehicle and ...
Over the past year, within retail pharmacy and IDNs, the U.S. hepatitis B market dose volume grew 23% year over year in Q3, while HEPLISAV-B dose volume grew 27%. These trends support our long-term ...